News
FDA panel vote dashes Intercept’s NASH hopes
Intercept Pharma is facing an uphill battle to get FDA approval of its OCA therapy for non-alcoholic steatohepatitis (NASH) once again, after FDA advisors comprehensively
Tuesday 5 November 2024
